STOCK TITAN

T2 Biosystems (TTOO) Stock Price, News & Analysis

TTOO OTC
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
118 211 sessions, November 17, 2025 to November 17, 2026
Largest daily move
+4900% close of November 9, 2026
1-year change
-96.7% closing prices, November 17, 2025 to November 17, 2026
1-month change
-42.9% closing prices, October 16, 2026 to November 17, 2026

Company Description

T2 Biosystems (OTC: TTOO) is classified in the diagnostics & research industry within the Healthcare sector and carries a market capitalization of $11.2K.

TTOO has declined 96.7% over the past year. The last closing price was $0.0004.

For FY2023, T2 Biosystems reported revenue of $7.2M with net income of -$50.1M and diluted earnings per share of -$19.19.

This page collects what Stock Titan holds for TTOO, including price data, latest news, SEC filings, financial highlights, and short interest trends.

Stock Performance

$0.0004
+0.00%
+0.0000
Last updated: at
-96.7%
Performance 1 year
$11.2K

T2 Biosystems (TTOO) closed at $0.0004 on November 17, 2026. Over the past 12 months, the price has lost 96.7%.

See what a $1,000 investment in TTOO would be worth today

Average down calculator for TTOO

TTOO Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

T2 Biosystems has 10 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, conferences, AI, fda approval. View all TTOO news →

SEC Filings

T2 Biosystems has filed 1 recent SEC filing, including 1 Form 25-NSE. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all TTOO SEC filings →

Financial Highlights

T2 Biosystems generated $7.2M in revenue in FY2023, operating income reached -$49.7M, and net income was -$50.1M. Diluted earnings per share stood at -$19.19. The company generated -$48.1M in operating cash flow. The current ratio was 0.45, measuring current assets divided by current liabilities.

$7.2M
Revenue (FY2023)
-$50.1M
Net Income (FY2023)
-$48.1M
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for TTOO.

Short Interest History

Last 12 Months

Short interest in T2 Biosystems (TTOO) currently stands at 4.9 thousand shares, representing 0.0% of the float.

Days to Cover History

Last 12 Months

Days to cover for T2 Biosystems (TTOO) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 3.5 days.

TTOO Company Profile & Sector Positioning

T2 Biosystems (TTOO) operates in the Diagnostics & Research industry within the broader Healthcare sector and is listed on the OTC.

Investors comparing TTOO often look at related companies in the same sector, including NovelStem Intl Corp (NSTM), Hypha Labs, Inc. (FUNI), StageZero Life Sciences (SZLSF), Avricore Health Inc (AVCRF), and RushNet Inc (RSHN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate TTOO's relative position within its industry.

Frequently Asked Questions

The current stock price of T2 Biosystems (TTOO) is $0.0004 as of November 17, 2026.

The market cap of T2 Biosystems (TTOO) is approximately $11.2K. Learn more about what market capitalization means .

The FY2023 revenue of T2 Biosystems (TTOO) is $7.2M, from its most recent completed fiscal year.

The FY2023 net income of T2 Biosystems (TTOO) is -$50.1M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of T2 Biosystems (TTOO) is -$19.19 for FY2023, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of T2 Biosystems (TTOO) is -$48.1M for FY2023, its most recent completed fiscal year. Learn about cash flow.

The current ratio of T2 Biosystems (TTOO), current assets divided by current liabilities, was 0.45 at the end of FY2023, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of T2 Biosystems (TTOO) is -$49.7M for FY2023, its most recent completed fiscal year. Learn about operating income.